#1 Clinical Trials Search in Europe

Study Comparing Pembrolizumab Alone and with Sacituzumab Govitecan for Patients with Metastatic Non-Small Cell Lung Cancer with High PD-L1 Levels

3 1 1 1

What is this study about?

This clinical trial is focused on studying a type of lung cancer known as Metastatic Non-small Cell Lung Cancer (NSCLC). The study is investigating the effectiveness of two treatments: Pembrolizumab, also known by its code name MK-3475, and Sacituzumab Govitecan. Pembrolizumab is a medication that helps the immune system fight cancer, while Sacituzumab Govitecan is another type of cancer treatment. The purpose of the study is to compare the effects of using Pembrolizumab alone versus using it in combination with Sacituzumab Govitecan.

Participants in the study will receive either Pembrolizumab by itself or a combination of Pembrolizumab and Sacituzumab Govitecan. These medications are given through an intravenous infusion, which means they are delivered directly into the bloodstream through a vein. The study will monitor how the cancer responds to these treatments over time, focusing on how long participants live without the cancer getting worse and their overall survival.

The trial will take place over a period of up to 24 months. During this time, participants will receive regular infusions and be closely monitored by healthcare professionals. The study aims to provide valuable information on the best treatment approach for patients with this type of lung cancer, helping to improve future care and outcomes for those affected by the disease.

1 joining the study

Upon joining the study, the diagnosis of metastatic non-small cell lung cancer is confirmed. It is verified that specific therapies are not indicated as primary treatment.

Tumor tissue is provided to demonstrate a PD-L1 tumor proportion score of 50% or more, assessed by a central laboratory.

2 treatment assignment

Participants are randomly assigned to one of two treatment groups: one receiving pembrolizumab alone, and the other receiving a combination of pembrolizumab and sacituzumab govitecan.

3 treatment administration

For those in the pembrolizumab group, the medication is administered as an intravenous infusion. The specific dosage and frequency are determined by the study protocol.

For those in the combination group, both pembrolizumab and sacituzumab govitecan are administered as intravenous infusions. The specific dosages and frequencies are determined by the study protocol.

4 monitoring and assessments

Participants undergo regular monitoring to assess progression-free survival and overall survival.

Additional assessments include objective response, duration of response, and changes in quality of life and physical functioning.

5 completion of study

The study is estimated to conclude by September 20, 2028. Participants continue to receive treatment and monitoring until the study’s end or until specific criteria for discontinuation are met.

Who Can Join the Study?

  • The patient must have a confirmed diagnosis of metastatic non-small cell lung cancer (NSCLC). This means the type of lung cancer has spread to other parts of the body.
  • The patient must have confirmation that certain treatments, specifically those targeting epidermal growth factor receptor (EGFR), anaplastic lymphoma kinase 1 (ALK-1), or ROS proto-oncogene 1 (ROS-1), are not suitable as the main treatment. These are specific proteins or genes that can affect cancer growth.
  • The patient must provide a sample of their tumor tissue showing a PD-L1 tumor proportion score (TPS) of 50% or more. This score is determined by a test called immunohistochemistry (IHC), which is done in a specialized lab. PD-L1 is a protein that can affect how the immune system responds to cancer.
  • The patient must have a life expectancy of at least 3 months, meaning they are expected to live for at least this amount of time.
  • Both male and female patients are eligible to participate.

Who Cannot Join the Study?

  • Patients with other types of cancer besides Metastatic Non-small Cell Lung Cancer cannot participate. This means the cancer has spread from the lung to other parts of the body.
  • Patients who have received certain treatments for their cancer recently may not be eligible. This includes treatments that could interfere with the study drugs.
  • Patients with serious health conditions that could affect their safety or the study results may be excluded. This includes conditions like severe heart disease or uncontrolled infections.
  • Patients who are pregnant or breastfeeding cannot participate, as the study drugs may affect the baby.
  • Patients who are unable to follow the study procedures or attend regular visits may not be eligible.
  • Patients who have had an allergic reaction to similar drugs in the past may be excluded to prevent any health risks.

Where you can join this trial?

Verified and Recommended Sites

No sites found in this category

Verified Sites

Site Name City Country Status
Azienda Ospedaliera Universitaria Federico II Di Napoli Naples Italy
Azienda Ospedaliero Universitaria Careggi Florence Italy

Other Sites

Site Name City Country Status
Centrul De Oncologie SF Nectarie S.R.L. Craiova Romania
Katholisches Klinikum Koblenz Montabaur gGmbH Koblenz Germany
Oncomed S.R.L. Timisoara Romania
Institute Of Oncology Prof. Dr. Ion Chiricuta Cluj-Napoca Cluj Napoca Romania
Ospedale P. Pederzoli Casa Di Cura Privata S.p.A. Peschiera Del Garda Italy
Szpital Specjalistyczny W Prabutach Sp. z o.o. Prabuty Poland
Klinikum Wuerzburg Mitte gGmbH Wuerzburg Germany
Vivantes Netzwerk fuer Gesundheit GmbH Berlin Germany
Pauls Stradins Clinical University Hospital Riga Latvia
Med Polonia Sp. z o.o. Poznan Poland
Tartu University Hospital Tartu Estonia
Narodowy Instytut Onkologii Im. Marii Sklodowskiej-Curie-Panstwowy Instytut Badawczy Warsaw Poland
Cardiomed S.R.L. Cluj Napoca Romania
Centrum Onkologii Im. Prof. Franciszka Lukaszczyka W Bydgoszczy Bydgoszcz Poland
HELIOS Klinikum Emil von Behring GmbH Berlin Germany
Lietuvos sveikatos mokslu universiteto ligonine Kauno klinikos Kaunas Lithuania
Radiotherapy Center Cluj S.R.L. Floresti Romania
Daugavpils regionala slimnica SIA Daugavpils Latvia
Mazowiecki Szpital Wojewodzki Im. Sw. Jana Pawła II W Siedlcach Sp. z o.o. Siedlce Poland
Klinikverbund Allgaeu gGmbH Kempten (Allgau) Germany
Szpital Rejonowy Im. Dr Jozefa Rostka W Raciborzu Raciborz Poland
Martha-Maria Krankenhaus Halle-Doelau gGmbH Halle (Saale) Germany
Henry Dunant Hospital Center Athens Greece
Fondazione I.R.C.C.S. Istituto Neurologico Besta Milan Italy
North Estonia Medical Centre Foundation Tallin Estonia
Thoracic General Hospital Of Athens I Sotiria Athens Greece
Deutsches Krebsforschungszentrum Stiftung Des Oeffentlichen Rechts Mannheim Germany
Vndepwshd iopgidjl Vcfwrjro ugzxxggyrliv lrvgjxwfv Snmkiykh kzifsdl fmvvqdwl Nsxbpaqlfuhu vpkhm cboxkni Vilnius Lithuania
Guho Mdezfog Shggyz Bucharest Romania
Awaehi Mqfrytu Cvdxak Sisg Thessaloniki Greece
Rspdu Afhrqzwr klmkadlp ukduehgmhhjit sfsugbmj Slq Riga Latvia
Alqbfvc Oplobbyxotq Unarahpryrnzy Pzhrt Parma Italy
Avxfzkx Oyglljprcag Pmqm Goelodvl Xdopk Bergamo Italy
Akaytve Oewzljkbnix S Glhmxebu Allsgktbqc Rome Italy
Wjwnjbdrur Stivcih Imj Sjahyba Pde W Pagcuvyik Przemysl Poland

Want to learn more about this study or check if you can participate? Contact us.

Trial status

Country Status Recruitment Start
Estonia Estonia
Not recruiting
14.02.2023
Germany Germany
Not recruiting
14.02.2023
Greece Greece
Not recruiting
14.02.2023
Italy Italy
Not recruiting
14.02.2023
Latvia Latvia
Not recruiting
14.02.2023
Lithuania Lithuania
Not recruiting
14.02.2023
Poland Poland
Not recruiting
14.02.2023
Romania Romania
Not recruiting
14.02.2023

Trial locations

Investigated drugs:

Pembrolizumab is a medication used in cancer treatment. It works by helping the immune system recognize and attack cancer cells. In this trial, it is being tested both alone and in combination with another medication to see how effective it is in treating a specific type of lung cancer.

Sacituzumab Govitecan is a type of targeted cancer therapy. It combines an antibody with a chemotherapy drug, allowing it to deliver the chemotherapy directly to cancer cells. In this trial, it is being used in combination with pembrolizumab to determine if the combination is more effective than pembrolizumab alone in treating lung cancer.

Investigated diseases:

Metastatic Non-small Cell Lung Cancer – This is a type of lung cancer that begins in the cells lining the lungs and has spread to other parts of the body. It is the most common type of lung cancer, accounting for about 85% of cases. The disease progresses as cancer cells grow and form tumors in the lungs, which can then metastasize to other organs such as the brain, bones, or liver. Symptoms may include persistent cough, chest pain, shortness of breath, and unexplained weight loss. As the cancer spreads, it can lead to more severe symptoms and complications depending on the organs affected. The progression of the disease can vary greatly among individuals, influenced by factors such as the cancer’s genetic makeup and the patient’s overall health.

Trial ID:
2023-503501-11-00
Protocol code:
MK-3475-D46
NCT ID:
NCT05609968
Trial Phase:
Therapeutic confirmatory (Phase III)

Other Trials to Consider

  • Study on the Safety and Effects of VERT-002 for Patients with Advanced Solid Tumors, Including Lung Cancer with MET Alterations

    Recruiting

    2 1 1
    Investigated drugs:
    Belgium France Germany Italy The Netherlands Spain

  • Evaluation of mRNA-4359 Monotherapy and Combined Pembrolizumab Therapy in Advanced Solid Tumors: A Phase 1/2 Clinical Trial

    Recruiting

    2 1 1 1
    Investigated drugs:
    Germany Italy Poland Spain